Fundai

Tehran Darou Pharmaceutical Company (DETEHRAN) cash flow statement

Operating, investing and financing cash flows, and the closing balance

Ticker
DETEHRAN
Industry
Pharmaceuticals
Market
IFB Base Market

Latest periods

Latest 12-month periods, in million rials
ItemTo 1404/12/29To 1403/12/30To 1402/12/29To 1401/12/29To 1400/12/29To 1399/12/30
Cash generated from operations1,333,4003,275,870453,462-1,275,074496,213-667,602
Cash payments for income tax-465,401-210,377-128,791-99,593-31,419-29,982
Net cash inflow (outflow) from operating activities867,9993,065,493324,671-1,374,667464,794-697,584
Cash payments for purchase of property, plant and equipment-2,871,521-840,655-920,376-594,731-112,600-145,616
Cash receipts from sale of short-term investments400,00000900,00000
Cash receipts from dividends50,67823,27124,500193,90312,12665,302
Cash receipts from interest on other investments466,94962,41015,762177,811160,8350
Net cash inflow (outflow) from investing activities-1,953,894-2,082,408-889,370632,479-363,521-544,514
Net cash inflow (outflow) before financing activities-1,085,895983,085-564,699-742,188101,273-1,242,098
Cash receipts from facilities11,756,6518,417,07612,048,2125,740,4214,114,0933,686,784
Cash payments for principal of loans-9,213,482-8,475,817-10,666,800-4,393,081-3,920,998-2,173,350
Cash payments for interest on loans-1,085,474-732,925-839,939-282,554-341,324-169,885
Cash payments for dividends-212,0030-262-178-72-12,000
Net cash inflow (outflow) from financing activities1,245,692-791,666541,2111,064,608-148,3011,331,549
Net increase (decrease) in cash159,797191,419-23,488322,420-47,02889,451
Cash balance at beginning of year674,321475,161496,611171,525216,146126,423
Effect of changes in exchange rates20,2557,7412,0382,6662,407272
Cash balance at end of year854,373674,321475,161496,611171,525216,146

Reporting periods

57 periods are on file for this report, from the period ending 1380/12/29 to the period ending 1404/12/29.